Tokyo Tape
Sign in
← M3

Quarterly report · Q3

2413.TEDINET S100Q51B
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥154.2bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥56.5bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥84.6bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥22.7bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥85.2bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.9bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥56.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.4bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥58.5bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥15.8bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥380.7bnat 2022-12-31Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥324.8bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥83.4bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥252.7bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥246.6bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.3bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥31.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥10.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥15.6bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥82.752021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.662021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥82.682021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.642021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥3.7bn
Reconciling Itemsreconcilingrevenue intersegment2021-10-01 → 2021-12-31−¥1.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2021-12-31−¥803m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥11.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥2.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥10.6bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥2.7bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥465m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥102m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.0bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥582m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥16.2bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥6.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥15.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥710m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥227m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.8bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-12-31¥64.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2021-10-01 → 2021-12-31¥26.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-12-31¥62.7bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2021-10-01 → 2021-12-31¥25.6bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥2.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥674m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-12-31¥30.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2021-10-01 → 2021-12-31¥14.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-12-31¥37.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-12-31¥37.8bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2021-10-01 → 2021-12-31¥13.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥5m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-12-31¥41.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2021-10-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-12-31¥25.7bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2021-10-01 → 2021-12-31¥8.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-12-31¥25.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2021-10-01 → 2021-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥438m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥200m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2021-10-01 → 2021-12-31¥2.0bn
—segment totalrevenue2021-04-01 → 2021-12-31¥155.4bn
—segment totalrevenue2021-10-01 → 2021-12-31¥56.8bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥151.8bn
—segment totalrevenue external2021-10-01 → 2021-12-31¥55.6bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥3.6bn
—segment totalrevenue intersegment2021-10-01 → 2021-12-31¥1.2bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥84.7bn
—segment totalsegment profit2021-10-01 → 2021-12-31¥21.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 789
ItemContextValueUnit
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-336000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration1299000000JPY
Gain relating to loss of control over subsidiaries IFRSPrior1YTDDuration9443000000JPY
Gain relating to loss of control over subsidiaries IFRSCurrentYTDDuration－JPY
Gain on change in equity IFRSPrior1YTDDuration21906000000JPY
Gain on change in equity IFRSCurrentYTDDuration－JPY
Other income IFRSPrior1YTDDuration1606000000JPY
Other income IFRSCurrentYTDDuration1592000000JPY
Other expenses IFRSPrior1YTDDuration116000000JPY
Other expenses IFRSCurrentYTDDuration160000000JPY
Operating profit loss IFRSPrior1YTDDuration84627000000JPY
Operating profit loss IFRSCurrentYTDDuration58734000000JPY
Finance income IFRSPrior1YTDDuration593000000JPY
Finance income IFRSCurrentYTDDuration1561000000JPY
Finance costs IFRSPrior1YTDDuration42000000JPY
Finance costs IFRSCurrentYTDDuration46000000JPY
Profit loss before tax IFRSPrior1YTDDuration85177000000JPY
Profit loss before tax IFRSCurrentYTDDuration60249000000JPY
Income tax expense IFRSPrior1YTDDuration26642000000JPY
Income tax expense IFRSCurrentYTDDuration18405000000JPY
Profit loss IFRSPrior1YTDDuration58535000000JPY
Profit loss IFRSCurrentYTDDuration41844000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration56169000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration39279000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration2366000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration2565000000JPY
Profit loss IFRSPrior1YTDDuration58535000000JPY
Profit loss IFRSCurrentYTDDuration41844000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration82.75
Basic earnings loss per share IFRSCurrentYTDDuration57.86
Diluted earnings loss per share IFRSPrior1YTDDuration82.68
Diluted earnings loss per share IFRSCurrentYTDDuration57.82
Revenue IFRSPrior1QuarterDuration56521000000JPY
Revenue IFRSCurrentQuarterDuration62538000000JPY
Cost of sales IFRSPrior1QuarterDuration21692000000JPY
Cost of sales IFRSCurrentQuarterDuration24816000000JPY
Gross profit IFRSPrior1QuarterDuration34830000000JPY
Gross profit IFRSCurrentQuarterDuration37723000000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration13380000000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration16045000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration126000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration685000000JPY
Other income IFRSPrior1QuarterDuration1150000000JPY
Other income IFRSCurrentQuarterDuration115000000JPY
Other expenses IFRSPrior1QuarterDuration39000000JPY
Other expenses IFRSCurrentQuarterDuration37000000JPY
Operating profit loss IFRSPrior1QuarterDuration22687000000JPY
Operating profit loss IFRSCurrentQuarterDuration22441000000JPY
Finance income IFRSPrior1QuarterDuration273000000JPY
Finance income IFRSCurrentQuarterDuration-245000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass